GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (XSWX:ATLNE) » Definitions » EV-to-EBIT

Actelion (XSWX:ATLNE) EV-to-EBIT : 8.91 (As of May. 02, 2024)


View and export this data going back to . Start your Free Trial

What is Actelion EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Actelion's Enterprise Value is CHF7,085 Mil. Actelion's EBIT for the trailing twelve months (TTM) ended in Mar. 2017 was CHF795 Mil. Therefore, Actelion's EV-to-EBIT for today is 8.91.

The historical rank and industry rank for Actelion's EV-to-EBIT or its related term are showing as below:

XSWX:ATLNE' s EV-to-EBIT Range Over the Past 10 Years
Min: -108.9   Med: 18.5   Max: 37.1
Current: 8.91

During the past 13 years, the highest EV-to-EBIT of Actelion was 37.10. The lowest was -108.90. And the median was 18.50.

XSWX:ATLNE's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 8.725 vs XSWX:ATLNE: 8.91

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Actelion's Enterprise Value for the quarter that ended in Mar. 2017 was CHF0 Mil. Actelion's EBIT for the trailing twelve months (TTM) ended in Mar. 2017 was CHF795 Mil. Actelion's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2017 was %.


Actelion EV-to-EBIT Historical Data

The historical data trend for Actelion's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion EV-to-EBIT Chart

Actelion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.79 16.64 20.83 22.10 28.19

Actelion Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.94 23.12 22.08 28.19 35.56

Competitive Comparison of Actelion's EV-to-EBIT

For the Biotechnology subindustry, Actelion's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actelion's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actelion's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Actelion's EV-to-EBIT falls into.



Actelion EV-to-EBIT Calculation

Actelion's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=7084.770/794.837
=8.91

Actelion's current Enterprise Value is CHF7,085 Mil.
Actelion's EBIT for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF795 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actelion  (XSWX:ATLNE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Actelion's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2017 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2017 ) =EBIT / Enterprise Value (Q: Mar. 2017 )
=794.837/0
= %

Actelion's Enterprise Value for the quarter that ended in Mar. 2017 was CHF0 Mil.
Actelion's EBIT for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF795 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actelion EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Actelion's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Actelion (XSWX:ATLNE) Business Description

Traded in Other Exchanges
N/A
Address
Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (XSWX:ATLNE) Headlines

No Headlines